LMR Partners’s Immunome IMNM Stock Holding History

LMR Partners’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-101,401	Closed	-$2.22M	–	1636
2026 Q1	$2.22M	Buy	101,401 +1,401	+1%	+$31.2K	﹤0.01%	833
2025 Q4	$2.15M	Buy	+100,000	New	+$1.76M	﹤0.01%	793

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

LMR Partners's IMNM Position: Q2 2026 in Review

LMR Partners sold out of Immunome (IMNM) in Q2 2026, closing a stake of 101,401 shares — an estimated $2.22M sold.

LMR Partners first reported a position in IMNM in Q4 2025 and held it in 2 quarters. The position peaked at $2.22M in Q1 2026. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

LMR Partners reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
LMR Partners sold 101,401 Immunome shares in Q2 2026, an estimated $2.22M.
LMR Partners first reported a position in Immunome in Q4 2025 and held it in 2 quarters.
LMR Partners's Immunome position peaked at $2.22M in Q1 2026.
203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.